Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radioactive drug safety tracked for years in rare cancer patients

NCT ID NCT05017662

Knowledge-focused Sponsor: Ariceum Therapeutics GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study follows 20 people with neuroendocrine tumors who previously received a radioactive drug called 177Lu-satoreotide tetraxetan. Researchers check for long-term side effects, including new cancers, every 3 months for up to 5 years. The goal is to understand the drug's safety over time, not to test if it works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
177Lu-satoreotide tetraxetan (a radioactive drug)
What this could lead to
If successful, this study will provide crucial safety data that could support the future use of this treatment for neuroendocrine tumors.
What could go wrong
This is a small, observational follow-up study with only 20 participants, so results may not apply to all patients. It does not test whether the treatment works, only its long-term safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Sep 2021

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant is capable of giving signed informed consent * Participant must have received at least one infusion of 177Lu-IPN01072 in Study OPS-C-001 Exclusion Criteria: \- There are no exclusion criteria in this safety surveillance study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neuroendocrine tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neuroendocrine tumors

Contacts and locations

Locations

  • Aarhus University Hospital

    Aarhus, 8200, Denmark

  • Hôtel Dieu de Nantes

    Nantes, 44093 Cedex 1, France

  • Medical University of Vienna

    Vienna, 1090, Austria

  • Peter Maccallum Cancer Center

    Melbourne, 3002, Australia

  • Ramsay Hollywood Private Hospital

    Perth, 6009, Australia

  • Royal Free Hospital London

    London, NW3 2QG, United Kingdom

  • University Hospital Basel

    Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.